title: Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma.
abstract: OBJECTIVE
  To retrospectively review our experience using radiation therapy as a palliative treatment in ovarian carcinoma.
  
  
  METHODS
  Eighty patients who received radiation therapy for ovarian carcinoma between 1983 and 1998 were reviewed. The indications for radiation therapy, radiation therapy techniques, details, tolerance, and response were recorded. A complete response required complete resolution of the patient's symptoms, radiographic findings, palpable mass, or CA-125 level. A partial response required at least 50% resolution of these parameters. The actuarial survival rates from initial diagnosis and from the completion of radiation therapy were calculated.
  
  
  RESULTS
  The median age of the patients was 67 years (range 26 to 90 years). A median of one laparotomy was performed before irradiation. Zero to 20 cycles of a platinum-based chemotherapy regimen were delivered before irradiation (median = 6 cycles). The reasons for palliative treatment were: pain (n = 22), mass (n = 23), obstruction of ureter, rectum, esophagus, or stomach (n = 12), a positive second-look laparotomy (n = 9), ascites (n = 8), vaginal bleeding (n = 6), rectal bleeding (n = 1), lymphedema (n = 3), skin involvement (n = 1), or brain metastases with symptoms (n = 11). Some patients received treatment for more than one indication. Treatment was directed to the abdomen or pelvis in 64 patients, to the brain in 11, and to other sites in 5. The overall response rate was 73%. Twenty-eight percent of the patients experienced a complete response of their symptoms, palpable mass, and/or CA-125 level. Forty-five percent had a partial response. Only 11% suffered progressive disease during therapy that required discontinuation of the treatment. Sixteen percent had stable disease. The duration of the responses and stable disease lasted until death except in 10 patients who experienced recurrence of their symptoms between 1 and 21 months (median = 9 months). The 1-, 2-, 3-, and 5-year actuarial survival rates from diagnosis were 89%, 73%, 42%, and 33%, respectively. The survival rates calculated from the completion of radiotherapy were 39%, 27%, 13%, and 10%, respectively. Five percent of patients experienced Grade 3 diarrhea, vomiting, myelosuppression, or fatigue. Fourteen percent of patients experienced Grade 1 or 2 diarrhea, 19% experienced Grade 1 or 2 nausea and vomiting, and 11% had Grade 1 or 2 myelosuppression.
  
  
  CONCLUSIONS
  In this series of radiation therapy for advanced ovarian carcinoma, the response, survival, and tolerance rates compare favorably to those reported for current second- and third-line chemotherapy regimens. Cooperative groups should consider evaluating prospectively the use of radiation therapy before nonplatinum and/or nonpaclitaxel chemotherapy in these patients.
authors.affiliation: Radiation Therapy Services, Fort Myers, FL, USA. atinger@rtsx.com
authors.forename: A
authors.initials: A
authors.lastname: Tinger
authors.forename: T
authors.initials: T
authors.lastname: Waldron
authors.forename: N
authors.initials: N
authors.lastname: Peluso
authors.forename: M J
authors.initials: MJ
authors.lastname: Katin
authors.forename: D E
authors.initials: DE
authors.lastname: Dosoretz
authors.forename: P H
authors.initials: PH
authors.lastname: Blitzer
authors.forename: J H
authors.initials: JH
authors.lastname: Rubenstein
authors.forename: G R
authors.initials: GR
authors.lastname: Garton
authors.forename: B A
authors.initials: BA
authors.lastname: Nakfoor
authors.forename: S J
authors.initials: SJ
authors.lastname: Patrice
authors.forename: L
authors.initials: L
authors.lastname: Chuang
authors.forename: J W
authors.initials: JW
authors.lastname: Orr
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D010166:Palliative Care; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012189:Retrospective Studies